Search

Your search keyword '"Receptor, PAR-1"' showing total 2,328 results

Search Constraints

Start Over You searched for: Descriptor "Receptor, PAR-1" Remove constraint Descriptor: "Receptor, PAR-1"
2,328 results on '"Receptor, PAR-1"'

Search Results

1. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.

2. Cell sheet produced from periodontal ligament stem cells activated by PAR1 improves osteogenic differentiation.

3. Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.

4. Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.

5. Compromised PAR1 Activation-A Cause for Bleeding in XMEN?

6. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4

7. Granzyme B promotes matrix metalloproteinase-1 (MMP-1) release from gingival fibroblasts in a PAR1- and Erk1/2-dependent manner: A novel role in periodontal inflammation.

8. Storage of Transfusion Platelet Concentrates Is Associated with Complement Activation and Reduced Ability of Platelets to Respond to Protease-Activated Receptor-1 and Thromboxane A2 Receptor.

9. Proteinase-activated Receptor-1 Antagonist Attenuates Brain Injury via Regulation of FGL2 and TLR4 after Intracerebral Hemorrhage in Mice

10. Thrombin induces a temporal biphasic vascular response through the differential phosphorylation of endothelial nitric oxide synthase via protease-activated receptor-1 and protein kinase C

11. Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery

12. An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay

13. Immunomodulatory role of thrombin in cancer progression

14. Myricetin reverses epithelial–endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting <scp>PAR1</scp>

15. Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?

16. High glucose upregulates PAR‐1 in SH‐SY5Y cells via deficiency of miR‐20a and miR‐190a

17. Lacticaseibacillus rhamnosus CRL1505 Peptidoglycan Modulates the Inflammation-Coagulation Response Triggered by Poly(I:C) in the Respiratory Tract.

18. Genomic and demographic processes differentially influence genetic variation across the human X chromosome.

19. Targeting PAR4 to Reduce Atherosclerosis.

20. Autoantibodies from patients with kidney allograft vasculopathy stimulate a proinflammatory switch in endothelial cells and monocytes mediated via GPCR-directed PAR1-TNF-α signaling.

21. Suppression of Heart Failure With PAR1 Pepducin Technology in a Pressure Overload Model in Mice.

22. Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes.

23. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.

24. Cell Responses of the Ventrolateral Medulla to PAR1 Activation and Changes in Respiratory Rhythm in Newborn Rat En Bloc Brainstem-Spinal Cord Preparations.

25. Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease

26. Relationship between the Responsiveness of Amyloid β Protein to Platelet Activation by TRAP Stimulation and Brain Atrophy in Patients with Diabetes Mellitus

27. KLK6/PAR1 Axis Promotes Tumor Growth and Metastasis by Regulating Cross-Talk between Tumor Cells and Macrophages

28. Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets

29. The Platelet Lipidome Is Altered in Patients with COVID-19 and Correlates with Platelet Reactivity

30. Manipulation of tissue factor-mediated basal PAR-2 signalling on macrophages determines sensitivity for IFNγ responsiveness and significantly modifies the phenotype of murine DTH

31. Gαq Is the Specific Mediator of PAR-1 Transactivation of Kinase Receptors in Vascular Smooth Muscle Cells

32. Recombinant Activated Protein C (rhAPC) Affects Lipopolysaccharide-Induced Mechanical Compliance Changes and Beat Frequency of mESC-Derived Cardiomyocyte Monolayers

33. A KLK4 proteinase substrate capture approach to antagonize PAR1

34. A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C)

35. Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

36. LPS-Induced Coagulation and Neuronal Damage in a Mice Model Is Attenuated by Enoxaparin

37. EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia

38. Osteogenesis in human periodontal ligament stem cell sheets is enhanced by the protease-activated receptor 1 (PARsub1/sub) in vivo

39. Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance

40. Serum protease-activated receptor (PAR-1) levels as a potential biomarker for diagnosis of inflammation in type 2 diabetic patients

41. Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran

42. Sarsasapogenin ameliorates diabetes‐associated memory impairment and neuroinflammation through down‐regulation of <scp>PAR</scp> ‐1 receptor

43. PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus

44. Plasminogen‐induced foam cell formation by macrophages occurs through a histone 2B (H2B)‐PAR1 pathway and requires integrity of clathrin‐coated pits

45. Enhanced thrombin/PAR1 activity promotes G-CSF- and AMD3100-induced mobilization of hematopoietic stem and progenitor cells via NO upregulation

46. Elevated expression of protease-activated receptor 1 via ΔNp63 down-regulation contributes to nodal metastasis in oral squamous cell carcinoma

47. Thrombin‐PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment

48. Protease-activated receptor 1 as a potential therapeutic target for COVID-19

49. The domino effect triggered by the tethered ligand of the protease activated receptors

50. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization

Catalog

Books, media, physical & digital resources